FDA NOMINATION OF JANET WOODCOCK, MD, AS NEW CDER DIRECTOR
• By The Tan Sheet
FDA NOMINATION OF JANET WOODCOCK, MD, AS NEW CDER DIRECTOR is awaiting final clearance at HHS. Woodcock, currently director of FDA's Center for Biologics Evaluation & Research's Office of Therapeutics Research and Review, was selected from a short list of candidates for the Center for Drug Evaluation & Research post submitted by a search committee to Deputy Commissioner for Operations Jane Henney, MD, in early November.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
Kwabena Frimpong-Manso Opuni has been appointed as the new acting CEO of the Ghana Food and Drugs Authority, succeeding Delese Darko, who is now head of the Africa’s pan-continental medicines agency.
The European Commission has published two new strategies on stockpiling that will improve the availability of critical medicines in times of crisis and reduce the EU’s dependance on suppliers outside the bloc.